TrialCancer medicine2025

BTK Inhibitor Synergizes With CD19-Targeted Chimeric Antigen Receptor-T Cells in Patients With Relapsed or Refractory B-Cell Lymphoma: An Open-Label Pragmatic Clinical Trial.

Wenjing Luo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.